Fontan's Operation — Cost, Top Hospitals & Success Rates | MyMedicPlus

Fontan's operation (the Fontan procedure) is a palliative cardiac surgery performed in children born with a single functional ventricle — a constellation of congenital heart defects in which only one of the two cardiac chambers is capable of pumping blood effectively. Rather than correcting the underlying anatomy to normal two-ventricle circulation, the Fontan procedure creates a bypass connecting the systemic veins directly to the pulmonary arteries, allowing deoxygenated blood to flow passively to the lungs without passing through the heart. The single functional ventricle is then dedicated entirely to pumping oxygenated blood through the systemic circulation.

First described by Francis Fontan in 1971, the procedure has undergone substantial evolution. The original atriopulmonary connection — which directed blood through the right atrium — has been superseded by modern total cavopulmonary connection (TCPC) techniques: the lateral tunnel (an intra-atrial baffle directing inferior vena cava flow to the pulmonary artery) and the extracardiac conduit (an externally placed prosthetic or homograft conduit bypassing the heart entirely). Contemporary modifications have reduced early mortality from 20–30% in early series to 1–2% at specialised centres.

The Fontan procedure is not performed in isolation — it represents the third and final stage of a planned staged surgical palliation sequence typically beginning in the neonatal period. Leading centres for Fontan surgery and long-term follow-up include specialised paediatric cardiac programmes in India (Narayana Health, Amrita), Singapore, Thailand, and Western Europe, where internationally trained congenital heart surgeons manage these complex cases.

Fontan's operation is indicated for a broad spectrum of complex congenital heart defects characterised by a functionally single ventricle, including:

• Hypoplastic left heart syndrome (HLHS): The left ventricle, aorta, and aortic valve are severely underdeveloped; Fontan is the third stage of the Norwood–Glenn–Fontan palliation sequence
• Tricuspid atresia: Absence or severe stenosis of the tricuspid valve with an absent or hypoplastic right ventricle
• Pulmonary atresia with intact ventricular septum: Right ventricular outflow obstruction with right ventricular hypoplasia
• Double-inlet left ventricle (DILV): Both atrioventricular valves drain into a single dominant left ventricle
• Heterotaxy syndromes (asplenia/polysplenia): Complex cardiac malpositions with ventricular imbalance
• Unbalanced atrioventricular septal defect: Where one ventricle is too hypoplastic for biventricular repair
• Double-outlet right ventricle with straddling AV valves: Selected anatomical variants not amenable to two-ventricle repair

Patient selection for Fontan completion surgery follows strict haemodynamic and anatomical criteria, collectively referred to as the 'Fontan criteria'. The ideal candidate has:

• A pulmonary artery pressure below 15–18 mmHg (measured at the time of bidirectional Glenn — Stage 2 — palliation)
• Pulmonary vascular resistance below 2–4 Wood units/m² — low resistance is essential for passive pulmonary blood flow
• Adequate pulmonary artery size (McGoon ratio >1.8 or Nakata index >250 mm²/m²)
• Good ventricular function of the single ventricle with ejection fraction >50%
• Normal or near-normal sinus rhythm — arrhythmia significantly worsens outcomes
• No significant atrioventricular valve regurgitation
• Typical age of 2–5 years at Fontan completion, following successful bidirectional Glenn at 3–6 months of age

Contraindications and risk factors that preclude or complicate Fontan surgery:

• Elevated pulmonary vascular resistance or pulmonary artery hypertension
• Small, distorted, or non-confluent pulmonary arteries
• Severe ventricular dysfunction or atrioventricular valve regurgitation
• Major systemic venous anomalies without adequate anatomical connections
• Significant systemic organ dysfunction (hepatic, renal)

The Fontan procedure is the culmination of a staged surgical programme. Understanding the full three-stage sequence is essential:

Stage 1 — Norwood / Damus-Kaye-Stansel (Neonatal, 1–2 weeks of age): In HLHS, the hypoplastic aorta is reconstructed to create a single systemic outflow from the right ventricle (neo-aorta). Pulmonary blood flow is provided via a systemic-to-pulmonary shunt (Blalock-Taussig-Thomas shunt) or right ventricle-to-pulmonary artery conduit (Sano modification). The atrial septum is removed to allow mixing. In other single-ventricle lesions, stage 1 may involve pulmonary artery banding (if over-circulation is the problem) or a systemic-to-pulmonary shunt (if under-circulation).

Stage 2 — Bidirectional Glenn (3–6 months of age): The superior vena cava (SVC) is divided from the heart and connected directly to the right pulmonary artery, allowing the upper body venous return to flow passively to both lungs. The systemic-to-pulmonary shunt is taken down. This reduces the volume load on the single ventricle and conditions the pulmonary vascular bed for the final Fontan connection.

Stage 3 — Fontan Completion / TCPC (18 months to 5 years): The inferior vena cava (IVC) blood — the remaining systemic venous return — is directed to the pulmonary arteries via one of two techniques:

• Lateral tunnel Fontan: A baffle is constructed inside the right atrium from the inferior vena cava to the pulmonary artery. Uses the patient's own atrial tissue; no foreign material. The fenestration (a small intentional hole between the Fontan circuit and the atrium) can be created at the time of surgery to allow a right-to-left 'pop-off' if Fontan pressures rise — reducing the risk of early Fontan failure at the cost of mild cyanosis
• Extracardiac conduit Fontan: A valved or non-valved prosthetic conduit (GORE-TEX, 18–20 mm) or homograft is placed outside the heart connecting the IVC directly to the pulmonary artery. Avoids extensive atrial surgery, minimises arrhythmia risk, and is the preferred technique at most high-volume centres. Can also be fenestrated

Fenestration: A small (4 mm) connection between the Fontan circuit and the atrium acts as a safety valve, reducing the risk of early post-operative low-output state. Associated with mildly lower oxygen saturations (85–90%) but significantly lower complication rates. Fenestration is typically closed transcathetally 6–12 months post-operatively once haemodynamic stability is confirmed.

The Fontan procedure is life-saving for children with single-ventricle anatomy — without it, survival beyond early childhood is extremely unlikely. Key outcomes at experienced centres include:

• Improved systemic oxygen saturation: Post-Fontan saturations of 90–95% (compared to 70–85% pre-Fontan), dramatically improving exercise tolerance, growth, and neurodevelopment
• Surgical survival: Early (30-day) mortality at experienced high-volume centres is 1–2% — a remarkable improvement from 20–30% in the early series of the 1970s
• Survival at 10 years: Approximately 85–90% in the modern era with extracardiac conduit technique
• Survival at 20–30 years: 70–85% for patients undergoing modern TCPC; long-term data from the current generation of Fontan patients continues to accrue
• Quality of life: The majority of Fontan patients achieve functional class I–II (New York Heart Association), participate in school and social activities, and achieve adult milestones including employment and, in women, pregnancy in selected cases
• Relief of cyanosis-related complications: Improved oxygen delivery reduces polycythaemia, coagulation abnormalities, and the systemic effects of chronic hypoxaemia

Fontan surgery carries significant short- and long-term risks that require lifelong specialist monitoring:

Early (peri-operative) complications:

• Pleural and pericardial effusions: The most common early complication, occurring in 30–50% of patients; passive venous pressure drives fluid accumulation; managed with chest drains, diuretics, and occasionally surgical re-intervention
• Early Fontan failure: Low cardiac output due to inadequate pulmonary blood flow; managed with fenestration, pulmonary vasodilators, or in severe cases, Fontan takedown
• Arrhythmias: Junctional ectopic tachycardia and other post-bypass arrhythmias; managed with cooling, amiodarone, and pacing
• Phrenic nerve injury: Diaphragmatic paralysis complicating weaning from ventilation

Late complications of Fontan circulation:

• Fontan-associated liver disease (FALD): Chronic venous congestion causes hepatic fibrosis and cirrhosis in virtually all long-term Fontan patients; progression to hepatocellular carcinoma is a recognised but uncommon late complication requiring surveillance
• Protein-losing enteropathy (PLE): Severe complication affecting 3–13% of Fontan patients; lymphatic and intestinal protein loss causing hypoalbuminaemia, ascites, and oedema; associated with poor prognosis without aggressive intervention
• Plastic bronchitis: Rare, severe complication of bronchial cast formation from lymphatic and chylous fluid leakage
• Arrhythmias (late): Atrial arrhythmias (intra-atrial re-entrant tachycardia, atrial fibrillation) affect 40–60% of patients at 20 years; require antiarrhythmic therapy, catheter ablation, or surgical maze procedure
• Thromboembolic events: Fontan circuit is prone to thrombus formation; lifelong anticoagulation (aspirin or warfarin) is standard; stroke risk is elevated
• Ventricular dysfunction: Progressive over decades in a subset of patients; ultimately leading to heart transplantation in 5–10% of adults with Fontan

Immediate post-operative period (ICU, Days 1–7): Patients are managed in the paediatric cardiac intensive care unit. Mechanical ventilation is typically weaned within 24–72 hours. Chest drains manage pleural effusions and are removed when output is minimal. Inotropic support, diuresis, and careful fluid management optimise Fontan haemodynamics. Pulmonary vasodilators (sildenafil) are used in selected cases.

Hospital ward (Days 7–21): Persistent pleural effusions are the main reason for prolonged hospital stay. A low-fat (medium-chain triglyceride) diet reduces chylous effusion. Anticoagulation is initiated. Oral diuretics and ACE inhibitors are commenced. Physical rehabilitation begins in hospital.

First 6 months at home: Activity is restricted but age-appropriate play is encouraged. Fenestration closure (if fenestrated) is performed at 6–12 months via transcatheter device occlusion. Cardiac MRI at 6–12 months provides baseline assessment of ventricular function and Fontan circuit patency.

Lifelong specialist follow-up (the Fontan surveillance programme):

• Annual cardiology review with echocardiography
• 24-hour Holter monitoring every 1–2 years for arrhythmia surveillance
• Cardiac MRI every 3–5 years for ventricular function and conduit assessment
• Annual liver function tests and hepatic ultrasound from age 10 (FALD surveillance); liver biopsy or fibroscan every 3–5 years in adolescents and adults
• Cardiac catheterisation every 5–10 years or when clinical concern arises
• Transition to adult congenital heart disease (ACHD) specialist care at age 16–18

Fontan surgery is among the most complex and resource-intensive paediatric cardiac procedures. Costs encompass the entire staged palliation programme and long-term follow-up. Indicative costs for the Fontan completion stage alone (not including prior staged surgeries):

• United States: USD 80,000–200,000 per stage; total three-stage palliation can exceed USD 500,000
• United Kingdom (NHS): Covered by the NHS for UK citizens; private or medical tourism cost GBP 40,000–80,000
• Germany / Netherlands: EUR 50,000–100,000 — leading European ACHD centres
• India (Narayana Health, AIIMS, Apollo): USD 8,000–20,000 per stage — making comprehensive staged palliation accessible to international families; several centres have performed hundreds of Fontan procedures with outcomes comparable to Western series
• Thailand (Bumrungrad, Bangkok Heart Hospital): USD 15,000–35,000
• Singapore: USD 30,000–60,000 at National Heart Centre Singapore

Key cost drivers include: surgical team experience and volume, ICU duration, complications (particularly prolonged pleural effusions), conduit material choice, implantable device needs (pacemaker, ICD), and the comprehensive multi-disciplinary team required (cardiac surgeon, interventional cardiologist, cardiac intensivist, hepatologist, haematologist). Medical tourism coordinators at specialised paediatric cardiac hospitals provide all-inclusive package quotes for international families.

• Staged palliation without Fontan completion: Some patients with favourable anatomy may achieve adequate palliation at the bidirectional Glenn stage with acceptable saturations (75–85%); Fontan completion is deferred if haemodynamic criteria are not met
• Biventricular conversion: In a minority of patients with borderline single-ventricle anatomy, conversion to biventricular physiology is occasionally possible through complex reconstructive surgery; outcomes are variable and must be weighed against Fontan completion
• Heart transplantation: The primary alternative when the Fontan pathway is not feasible due to elevated pulmonary vascular resistance, or as rescue therapy for failed Fontan circulation. Approximately 5–10% of adult Fontan patients ultimately require cardiac transplantation
• Pulmonary vasodilator therapy (Fontan support): Phosphodiesterase-5 inhibitors (sildenafil, tadalafil) and endothelin receptor antagonists (bosentan) are being studied to improve Fontan haemodynamics and delay failure, though they are not a substitute for surgery
• Cardiac resynchronisation therapy (CRT) / ICD: For patients with Fontan failure complicated by ventricular dyssynchrony or malignant arrhythmia, device therapy may provide symptomatic benefit